A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
Ultra-fast biparametric magnetic resonance imaging (bpMRI) may provide a viable alternative to multiparametric MRI (mpMRI) for the detection of clinically significant prostate cancer (csPCa), according to new study findings presented at the European Congress of Radiology (ECR) conference.
For the prospective study, researchers compared mpMRI and deep learning-assisted ultra-fast bpMRI for detection of csPCa in 123 biopsy-naïve patients. Two radiologists, with four and three years of experience, respectively, offered PI-RADS v2.1 assessments as well as PI-QUAL scores for image quality, according to the study.
The researchers found that the ultra-fast bpMRI protocol offered similar sensitivity (91 percent vs. 94 percent) and negative predictive value (NPV) (95 percent vs. 96 percent) for csPCa detection as mpMRI.
In a study recently presented at the European Congress of Radiology (ECR) conference, researchers found that a deep learning-assisted ultra-fast bpMRI protocol offered similar sensitivity (91 percent vs. 94 percent) and negative predictive value (NPV) (95 percent vs. 96 percent) for csPCa detection as mpMRI.
“There was no significant difference in the diagnostic performance of correctly identifying csPCa between both protocols,” wrote lead study author Antonia-Maria Pausch, M.D., a fellow at the Institute for Diagnostic and Interventional Radiology at the University Hospital Zurich in Zurich, Switzerland, and colleagues.
The study authors pointed out that the more experienced reviewing radiologist’s assessments with ultra-fast bpMRI had 25 percent higher specificity, 17 percent higher positive predictive value (PPV) and 17 percent higher accuracy rates than the evaluations of the radiologist with three years of experience.
(Editor’s note: For related content, see “Can MRI-Based Deep Lrearning Improve Risk Stratification in PI-RADS 3 Cases?,” “Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Diagnosis?” and “Emerging AI Platform Shows Promise for Prostate Cancer Detection on mpMRI.”)
Otherwise, the researchers noted 87 percent inter-reader agreement for ultra-fast bpMRI in comparison to 83 percent for mpMRI for csPCa. The study authors also higher PI-QUAL ratings and emphasized an 80 percent reduction in scan time with ultra-fast bpMRI.
“Deep-learning-assisted ultra-fast bpMRI protocols offer a promising alternative to conventional mpMRI for diagnosing csPCa in biopsy-naïve patients with comparable inter-reader agreement and diagnostic performance at superior image quality,” added Pausch and colleagues.
Reference
1. Pausch AM, Fillebock V, Elsner C, Rupp N, Eberli D, Hotker AM.Ultra-fast biparametric MRI in prostate cancer assessment: diagnostic performance and image quality compared to conventional multiparametric MRI. Presented at the European Congress of Radiology (ECR), February 26-March 2, 2025, Vienna, Austria. Available at https://www.myesr.org/congress/ . Accessed March 1, 2025.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.